Overview

Triumeq in Amyotrophic Lateral Sclerosis

Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
To determine if Triumeq improves survival in Amyotrophic Lateral Sclerosis (ALS) compared with placebo
Phase:
Phase 3
Details
Lead Sponsor:
Macquarie University, Australia
Collaborators:
King's College London
Stichting TRICALS Foundation
Treatments:
Abacavir
Dolutegravir
Lamivudine
Triumeq